Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.

ABSTRACT:

Objectives

To investigate safety and efficacy of MMF in patients with severe or MTX-refractory juvenile localized scleroderma.

Methods

Consecutive juvenile localized scleroderma patients undergoing systemic treatment were included in a retrospective longitudinal study. Patients treated with MMF because they were refractory or intolerant to MTX (MMF-group) were compared with responders to MTX (MTX-group). Disease activity was assessed by Localized Scleroderma Cutaneous Assessment Tool and thermography. Disease course was established on the number of relapses and treatment changes. Relapse-free survival was examined by Kaplan-Meier analysis.

Results

MMF and MTX groups included 22 and 47 patients, respectively. No significant difference in demographics, follow-up duratio

SUBMITTER: Martini G 

PROVIDER: S-EPMC7937018 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature